Workshop A – Pinpointing Suitable Models for Novel Compounds to Garner Successful Translation to Clinic

Time: 9:00 am
day: Pre-Conference Workshop Day


Identifying indications where your compound is most likely to succeed is key, and

good preclinical models are in short supply in the Hippo Pathway Space. Here, the

team from Fred Hutch unveil a host of preclinical modeling programs that have been

specifically tailored for targeting Hippo pathway in a multitude of indications. Yap

gene fusions are found in many cancer types and they are able to determine which

of them are sufficient to induce tumors, and what mechanisms drive oncogenesis.

These mouse models can be used to identify and test therapies in vivo aimed at

YAP/TEAD stability and interaction.

Bring the pharmacology of your lead candidate compound and together with the

team from Fred Hutch, decipher which models will enable most efficacy.

Attend this workshop to:

  • Uncover mechanistic insights glioblastomas, lung cancer, and the other cancer types and how this has been translated into hippo pathway models
  • Match your leading drug candidate compound targeting TEAD to suitable preclinical models or dysregulated hippo pathway